# A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects

Study · id `cardio:ct-nct01652703` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01652703](<https://clinicaltrials.gov/study/NCT01652703>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01652703

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 310 participants.

## Technical summary

Registry record NCT01652703. Randomized; triple masking; primary purpose treatment. Start 2012-07-10 (actual); primary completion 2013-05-14 (actual). Results posted on 2015-10-05.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 310 participants (enrolled count; ClinicalTrials.gov record NCT01652703, source copy `cardio:ctgov-nct01652703-2018-11-28`, retrieved 2026-10-31)
- Started: 2012-07-10 (actual) (ClinicalTrials.gov record NCT01652703, source copy `cardio:ctgov-nct01652703-2018-11-28`, retrieved 2026-10-31)
- Primary completion: 2013-05-14 (actual) (ClinicalTrials.gov record NCT01652703, source copy `cardio:ctgov-nct01652703-2018-11-28`, retrieved 2026-10-31)
- Completion: Not reported
- Results first posted: 2015-10-05 (ClinicalTrials.gov record NCT01652703, source copy `cardio:ctgov-nct01652703-2018-11-28`, retrieved 2026-10-31)
- Countries: Japan (ClinicalTrials.gov record NCT01652703, source copy `cardio:ctgov-nct01652703-2018-11-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01652703-2018-11-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects
- Acronym: AMG145
- Condition: Hypercholesterolemia and High Risk for Cardiovascular Events
- Intervention (Biological): Evolocumab
- Intervention (Other): Placebo
- Lead sponsor: Amgen
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Amgen (`cardio:org-amgen`)

## Provenance

Content hash: 9f663e5e8336cbe2adbac647aef9aff3b922e97cee224d77c6e2c82384978c5b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
